Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688266'
s Net Margin % Range Over the Past 10 Years
Min: -64134 Med: -194.1 Max: 32.16
Current: 32.16
SHSE:688266's Net Margin % is ranked better than 91.19% of 942
companies
in the Biotechnology industry
Industry Median: -88.815
vs SHSE:688266: 32.16
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Suzhou Zelgen Biopharmaceuticals Co Net Margin % Related Terms
Suzhou Zelgen Biopharmaceuticals Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co Net Margin % Chart
SHSE:688266 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Zelgen Biopharmaceuticals Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Net Margin % of 69.87% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #83 out of 942 companies in the Biotechnology industry, placing it in the top 8.8%.
Is Suzhou Zelgen Biopharmaceuticals Co's Net Margin % too high?
Suzhou Zelgen Biopharmaceuticals Co's current Net Margin % is 69.87%. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #83 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #83 out of 942 companies for Net Margin %. This places Suzhou Zelgen Biopharmaceuticals Co in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. Suzhou Zelgen Biopharmaceuticals Co's current Net Margin % is 69.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥216.30, compared to a current price of ¥140.00 — trading 35.3% below its estimated fair value. The current Net Margin % is 69.87%. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Net Margin % is 69.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥140.00 is trading 35.3% below its estimated GF Value™ of ¥216.30.
GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for SHSE:688266:
Net Margin %: 69.87%
GF Value™: ¥216.30 vs. price of ¥140.00 (35.3% below fair value)
No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Zelgen Biopharmaceuticals Co Business Description
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
67GF Score
Get the complete analysis for SHSE:688266
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688266 has been successfully added to your 
